Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells.

Pepke W, Eisenreich A, Jaster M, Ayral Y, Bobbert P, Mayer A, Schultheiss HP, Rauch U.

Cardiovasc Ther. 2013 Apr;31(2):115-23. doi: 10.1111/j.1755-5922.2011.00305.x. Epub 2011 Dec 29.

PMID:
22212466
5.

Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.

Anand SX, Kim MC, Kamran M, Sharma SK, Kini AS, Fareed J, Hoppensteadt DA, Carbon F, Cavusoglu E, Varon D, Viles-Gonzalez JF, Badimon JJ, Marmur JD.

Am J Cardiol. 2007 Aug 1;100(3):417-24. Epub 2007 Jun 13.

PMID:
17659921
6.

Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation.

Schneider DJ, Sobel BE.

Coron Artery Dis. 2009 Mar;20(2):175-8. doi: 10.1097/MCA.0b013e32831edcd1.

PMID:
19194284
7.

Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality.

Ndrepepa G, Schulz S, Keta D, Mehilli J, Birkmeier A, Massberg S, Laugwitz KL, Neumann FJ, Seyfarth M, Berger PB, Schömig A, Kastrati A.

Am J Cardiol. 2010 Jan 15;105(2):163-7. doi: 10.1016/j.amjcard.2009.08.668. Epub 2009 Nov 14.

PMID:
20102912
8.

Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.

Fiedler KA, Ndrepepa G, Schulz S, Floh S, Hoppmann P, Kufner S, Bernlochner I, Byrne RA, Schunkert H, Laugwitz KL, Kastrati A.

EuroIntervention. 2016 Feb;11(11):e1275-82. doi: 10.4244/EIJV11I11A249.

9.

Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention.

Busch G, Steppich B, Sibbing D, Braun SL, Stein A, Groha P, Schömig A, Kastrati A, von Beckerath N, Ott I.

Thromb Haemost. 2009 Feb;101(2):340-4.

PMID:
19190819
10.

Comparison of bivalirudin and heparin in patients undergoing rotational atherectomy: a subanalysis of the randomised ROTAXUS trial.

Akin I, Khattab AA, Büttner HJ, Toelg R, Geist V, Neumann FJ, Richardt G, Abdel-Wahab M.

EuroIntervention. 2014 Aug;10(4):458-65. doi: 10.4244/EIJV10I4A79.

11.

Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).

Patti G, Pasceri V, D'Antonio L, D'Ambrosio A, Macrì M, Dicuonzo G, Colonna G, Montinaro A, Di Sciascio G.

Am J Cardiol. 2012 Aug 15;110(4):478-84. doi: 10.1016/j.amjcard.2012.04.017. Epub 2012 May 12.

PMID:
22583760
12.

Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.

Feldman DN, Wong SC, Gade CL, Gidseg DS, Bergman G, Minutello RM.

Am Heart J. 2007 Oct;154(4):695-701. Epub 2007 Aug 20.

PMID:
17892994
13.
14.

Bivalirudin versus unfractionated heparin for residual thrombus burden: a frequency-domain optical coherence tomography study.

Vergallo R, Joye R, Barlis P, Jia H, Tian J, Soeda T, Minami Y, Hu S, Dauerman HL, Toma C, Chan J, Lee H, Biasucci LM, Crea F, Jang IK.

Catheter Cardiovasc Interv. 2015 Mar;85(4):575-82. doi: 10.1002/ccd.25631. Epub 2014 Aug 22.

PMID:
25115992
15.

Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.

Gurbel PA, Bliden KP, Saucedo JF, Suarez TA, DiChiara J, Antonino MJ, Mahla E, Singla A, Herzog WR, Bassi AK, Hennebry TA, Gesheff TB, Tantry US.

J Am Coll Cardiol. 2009 Feb 24;53(8):648-57. doi: 10.1016/j.jacc.2008.10.045.

16.

Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention.

Sibbing D, Busch G, Braun S, Jawansky S, Schömig A, Kastrati A, Ott I, von Beckerath N.

Eur Heart J. 2008 Jun;29(12):1504-9. doi: 10.1093/eurheartj/ehn195. Epub 2008 May 7.

PMID:
18467322
17.

Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention.

MacHaalany J, Abdelaal E, Bataille Y, Plourde G, Duranleau-Gagnon P, Larose É, Déry JP, Barbeau G, Rinfret S, Rodés-Cabau J, De Larochellière R, Roy L, Costerousse O, Bertrand OF.

Am J Cardiol. 2012 Dec 15;110(12):1742-8. doi: 10.1016/j.amjcard.2012.07.043. Epub 2012 Sep 14.

PMID:
22980964
18.

Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.

Deshpande NV, Pratiti R, Admane P, Mukherjee D, Mardikar HM.

Indian Heart J. 2012 Sep-Oct;64(5):444-8. doi: 10.1016/j.ihj.2012.07.022. Epub 2012 Jul 27.

19.

Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial.

Khattab AA, Ndrepepa G, Schulz S, Neumann FJ, Mehilli J, Büttner HJ, Pache J, Seyfarth M, Dirschinger J, Kastrati A, Berger PB, Schömig A, Richardt G.

Clin Res Cardiol. 2011 Jul;100(7):579-85. doi: 10.1007/s00392-011-0282-7. Epub 2011 Feb 11.

PMID:
21311899
20.

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).

Waksman R, Bertrand O, Driesman M, Gruberg L, Rossi J, Mehta S, Swymelar S, Dvir D, Xue Z, Torguson R.

J Interv Cardiol. 2013 Apr;26(2):107-13. doi: 10.1111/joic.12005. Epub 2012 Dec 13.

PMID:
23240743

Supplemental Content

Support Center